Check for updates

OPEN ACCESS

EDITED BY Yasmina Mohammed Abd EL-Hakim, Zagazig University, Egypt

REVIEWED BY Hui Yan, Nanjing University of Chinese Medicine, China Thanh-Tam Ho, Duy Tan University, Vietnam

*CORRESPONDENCE Feng Wei, weifeng@nifdc.org.cn Shuangcheng Ma, masc@nifdc.org.cn

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

RECEIVED 03 May 2022 ACCEPTED 13 July 2022 PUBLISHED 26 August 2022

CITATION

Song Y, Yang J, Hu X, Gao H, Wang P, Wang X, Liu Y, Cheng X, Wei F and Ma S (2022), A stepwise strategy integrating metabolomics and pseudotargeted spectrum–effect relationship to elucidate the potential hepatotoxic components in *Polygonum multiflorum. Front. Pharmacol.* 13:935336. doi: 10.3389/fphar.2022.935336

COPYRIGHT

© 2022 Song, Yang, Hu, Gao, Wang, Wang, Liu, Cheng, Wei and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A stepwise strategy integrating metabolomics and pseudotargeted spectrum–effect relationship to elucidate the potential hepatotoxic components in *Polygonum multiflorum*

Yunfei Song^{1,2†}, Jianbo Yang^{2†}, Xiaowen Hu², Huiyu Gao², Pengfei Wang², Xueting Wang², Yue Liu¹, Xianlong Cheng², Feng Wei²* and Shuangcheng Ma^{1,2}*

¹School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China, ²Institute for Control of Chinese Traditional Medicine and Ethnic Medicine, National Institutes for Food and Drug Control, Beijing, China

Polygonum multiflorum (PM) Thunb., a typical Chinese herbal medicine with different therapeutic effect in raw and processed forms, has been used worldwide for thousands of years. However, hepatotoxicity caused by PM has raised considerable concern in recent decades. The exploration of toxic components in PM has been a great challenge for a long time. In this study, we developed a stepwise strategy integrating metabolomics and pseudotargeted spectrum-effect relationship to illuminate the potential hepatotoxic components in PM. First, 112 components were tentatively identified using ultraperformance liquid chromatography-quadrupole-time-of-flight-mass spectrometry (UPLC-Q-TOF-MS). Second, based on the theory of toxicity attenuation after processing, we combined the UPLC-Q-TOF-MS method and plant metabolomics to screen out the reduced differential components in PM between raw and processed PM. Third, the proposed pseudotargeted MS of 16 differential components was established and applied to 50 batches of PM for quantitative analysis. Fourth, the hepatocytotoxicity of 50 batches of PM was investigated on two hepatocytes, LO2 and HepG2. Last, three mathematical models, gray relational analysis, orthogonal partial least squares analysis, and back propagation artificial neural network, were established to further identify the key variables affecting hepatotoxicity in PM by combining quantitative spectral information with toxicity to hepatocytes of 50 batches of PM. The results suggested that 16 components may have different degrees of hepatotoxicity, which may lead to hepatotoxicity through synergistic effects. Three components (emodin dianthrones, emodin-8- $O-\beta$ -D-glucopyranoside, PM 14-17) were screened to have significant hepatotoxicity and could be used as toxicity markers in PM as well as for further studies on the mechanism of toxicity. Above all, the study established an effective strategy to explore the hepatotoxic material basis in PM but also provides reference information for indepth investigations on the hepatotoxicity of PM.

KEYWORDS

polygonum multiflorum, hepatotoxicity, pseudotargeted spectrum-effect relationship, plant metabolomics, mathematical model

1 Introduction

Polygonum multiflorum (PM) Thunb., known as one of the "Four Great Herbs" in ancient China (PM, Ginseng, Ganoderma lucidum, Cordyceps sinensis), is widely used in many Chinese prescriptions and patent medicines due to its remarkable therapeutic effects. As early as the Song dynasty, the historical Chinese medicine document "Kai Bao Ben Cao" recorded the pharmacological efficacy of PM as "strengthen muscles and bones, benefit the essence, prolong life" (Lei et al., 2015; Teka et al., 2021). With different therapeutic effects, in general, PM can be divided into raw and processed PM in clinical applications. The Chinese pharmacopoeia states that raw PM has the effects of detoxification, eliminating carbuncles, moistening the intestine, and relieving constipation, while the processed product has been used mainly to tonify the liver and kidney, nourish blood, blacken hair, strengthen the body, dissolve turbidity, and lower blood lipid levels (Chinese Pharmacopoeia Commission, 2020). Meanwhile, modern pharmacological research has shown that the main active ingredients of PM are stilbene glycosides, anthraquinones, glycosides, phospholipids, flavonoids and others, which significantly contribute to delaying senescence, preventing cardiovascular diseases, tonifying the kidney and hair, improving intelligence, enhancing immune function, protecting the liver, moistening the intestine, and defecating as well as have antibacterial and antiinflammatory effects (Lin et al., 2015; Liu et al., 2018).

However, since the 1990s, there has been a rapid increase in reports of liver damage caused by PM, which has attracted attention at home and abroad (But et al., 1996; Park et al., 2001; Han et al., 2019). Thereafter, the drug supervision and administration departments of the United Kingdom, Japan, and China successively issued warnings or regulatory measures for the risk of liver damage from PM and its preparations. In fact, the ancient textbook "Ben Cao Hui Yan" recorded "Polygonum multiflorum, taste bitter, astringent, flavor mild, slightly toxic." Processed PM can significantly relieve the toxicity and change the efficacy of PM, and a relatively complete processing method for PM was used in the Song dynasty. Modern pharmacological studies have also confirmed that processing can greatly reduce the risk of hepatotoxicity of PM. However, the chemical composition of PM is complex and diverse, and PM mainly includes stilbenes, anthraquinones, anthranone, glycosides, phospholipids, flavonoids, and tannins (Lin et al., 2015; Teka et al., 2021). The issue of which components of PM cause hepatotoxicity remains a major subject that needs to be addressed.

In general, the traditional research approach was to first isolate and identify compounds from PM and then to evaluate the compounds for hepatotoxicity *in vivo* or *in vitro*. This process was time-consuming and laborious but also neglected the synergistic toxic effects of the compounds in PM, so the hepatotoxicity of PM could not be comprehensively evaluated. Therefore, it was imperative to develop an effective scientific strategy to efficiently screen out the toxic components of PM.

In recent years, with the development of high-resolution mass spectrometry (MS) and metabolomics techniques, ultraperformance liquid chromatography-quadrupole-timeof-flight-MS (UPLC-Q-TOF-MS) has made it possible to characterize complex components in PM in a short time, and metabolomics combined with chemometrics has enabled the rapid search for differential markers between raw and processed PM (Liu et al., 2016; Shang et al., 2021). Moreover, spectrum-efficiency relationship research has opened a new window for the evaluation of modern traditional Chinese medicine (TCM), which combines the complex chemical information of TCM with pharmacological efficacy and screens the important features related to the efficacy by means of chemometric statistical methods or machine learning (Zhang et al., 2018; Rao et al., 2022). In particular, great progress has been made in the joint analysis of the spectrum-effect relationship based on fingerprinting and pharmacodynamics for illuminating active ingredient markers in complex TCMs. However, the lack of ultraviolet absorption of many compounds and trace components and the lack of standard reference materials pose serious challenges for absolute quantification. Xu's proposed pseudotargeted metabolomics, establishing a scheduled MRM method for the semiquantification of metabolites, gave us an inspiration of what to do (Luo et al., 2015; Zheng et al., 2020). Compared with previous methods, the established UPLCcoupled scheduled MRM method was a more powerful technique with significant advantages of high sensitivity, wide universality, low matrix effects, and accurate quantification.

In the current study, a stepwise strategy integrating metabolomics and pseudotargeted spectrum-effect relationship was set up to clarify the potential hepatotoxic components in PM (Figure 1). First, the chemical composition of PM was comprehensively characterized



using UPLC-Q-TOF-MS. Second, based on the theory of detoxification after PM processing, the distinctive differential components between raw and processed PM were screened out using plant metabolomics. Third, the proposed pseudotargeted MRM semiquantitative profiles of the differential marked components were established in different batches of PM. Fourth, the toxicity of various batches of PM to the hepatocytes L02 and HepG2 was investigated. At last, gray relational analysis (GRA), orthogonal partial least squares (OPLS) analysis, and back propagation artificial neural network (BP-ANN) models were established to correlate the peak areas of pseudotargeted spectra with the IC₅₀ values of toxicity to further obtain the hepatotoxic components in PM.

2 Materials and methods

2.1 Materials and reagents

Methanol and acetonitrile of LC/MS grade were obtained from Merck (Darmstadt, Germany). High-performance liquid chromatography-grade ethanol and dimethyl sulfoxide (DMSO) were obtained from Sinopharm Chemical Reagent Co., Ltd (Shanghai, China). Ultra-pure water was prepared using a Milli-Q system (Billerica, MA, United States). Standard products of stilbene glycoside, emodin, etc., were provided by the China National Institute for Food and Drug Control. Physcion-8-O- β -D-glucopyranoside, physcion-1-O- β -D-glucopyranoside, and aloeemodin-3-hydroxymethyl- β -D-glucopyranoside were purchased from Standard Technology Co., Ltd (Shanghai, China). The purity of all standards was above 98%. Formic acid was acquired from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). A 0.22-µm filter membrane was purchased from Dikema Technology Co., Ltd. (Beijing, China).

The hepatic cell lines HepG2 and L02 were obtained from the cell bank of the Chinese Academy of Sciences (Shanghai, China). Dulbecco's Modified Eagle Medium (DMEM) and Roswell Park Memorial Institute (RPMI) 1640 culture medium (Biological Industries, Israel), fetal bovine serum (FBS; France), Biosera. 1% penicillin-streptomycin (Targetmol, China), and 0.25% trypsinethylenediaminetetraacetic acid (Wisent, Canada) were used for cell culture. Staurosporine (STSP) and CCK-8 reagent were obtained from Targetmol (Shanghai, China). A total of 384 cell culture plates were purchased from Jet Bio-Filtration Co., Ltd. (Guangzhou, China). The Victor Nivo multimode plate reader was from PerkinElmer (Shanghai, China).

Sample A: 36 batches of raw and processed PM from different origins or batches. In total, 0.1 g was taken from each batch to make 10 portions of mixed samples as quality control (QC). Sample B: 30 batches of raw PM and 20 batches of processed PM. Samples A and B all met the requirements of the Chinese pharmacopoeia. The samples were stored at the China National Institute for Food and Drug Control (Beijing, China). Detailed sample information can be found in Supplementary Tables S1, S2.

2.2 Sample and standard solution preparation

Sample A (46 samples in total, filtered through a No. 3 sieve): The sample (1.0 g) was weighed precisely and placed in a 50-mL conical flask. Then, 50 mL of 70% ethanol was added, and the mixture was weighed, sonicated for 30 min, cooled, and replenished. The extracted solution was collected for UPLC-Q-TOF-MS analysis.

The standard solution was prepared by weighing 1 mg of standard powder and adding 2 ml of methanol solution to dissolve it for the qualitative test. All standard and sample solutions were filtered through 0.22- μ m Millipore filtration before injection.

Sample B (50 samples): 20 g of PM was weighed and extracted with 300 ml of 70% ethanol three times for 30 min each time. Then, the extracted solutions were combined and concentrated under pressure and subsequently freeze-dried to powder. The dry extract powder weighing 40 mg was dissolved in 40 ml of 70% ethanol solution for UPLC-qqq-MS/MS analysis. Of note, 30 mg of dried extract powder was weighed precisely and prepared as a storage solution of 200 mg/ml. Then, a series of concentrations of working solutions (1,000, 400, 160, 64, 25, 10, and 4 μ g/ml) was obtained by gradient dilution with culture medium for the *in vitro* cytotoxicity assay.

2.3 Ultraperformance liquid chromatography-quadrupole-time-offlight-mass spectrometry analysis

2.3.1 Chemical composition characterization

The extract solution of the PM mixed sample in sample A was analyzed using UPLC-Q-TOF-MS. Analysis was performed using an AcquityTM UPLC Class I system equipped with a photodiode array (PDA) detector and Q-TOF SYNAPTG2-Si (Waters, Manchester, United States). Chromatographic conditions: The temperature of the column and autosampler was maintained at 40°C and 6°C. The flow rate was 0.3 ml/min, and the injection volume was 1 µl. The binary mobile phase contained solvent A (0.1% FA in deionized water, v/v) and

solvent B (methanol, LC-MS grade). The peptides of the elution gradient were initial 10% B, linear gradient 40% B (22 min), 70% B (33 min), 100% B (44-46 min), 10% B (46.2 min), and holding 10% B to 50 min. The PDA detector used 3D range from 190 to 400 nm. MS conditions: The UPLC-MS system was operated in the negative ion and MS^E data acquisition mode. Experimental parameters were set as follows: capillary voltage at -2.5 kV (ESI⁻); source temperature at 115°C; cone voltage at 40 V; ramp trap MS collision energy of 20-50 V; desolvation temperature at 450°C; cone gas flow of 50 L/ h; desolvation gas flow of 900 L/h; and scan range of m/z50-1,500 Da. At the same time, an external reference consisting of 1.0 ng/ml solution of leucine enkephalin was used to produce a reference ion at m/z 554.2615 Da ([M-H]⁻) in negative ion mode for real-time mass correction during acquisition. The obtained mass spectrometric data were analyzed using UNIFI software in combination with a selfbuilt database of PM compounds and reference standards as well as fragment ion matching strategies to fully characterize the components of PM.

2.3.2 Plant metabolomics analysis

Processed sample A (n = 46) was analyzed using UPLC-Q-TOF-MS under the same chromatographic and mass spectrometric conditions as in Section 2.3.1. The acquired data were further deconvolved into a data matrix (Rt-m/z-intensity) by Progenesis QI software (Waters, Milford, MA, United States). After further data preprocessing, chemometric (principal component analysis (PCA), PLS-DA, OPLS-DA) analysis was performed using Simca-P 14.1 software. Combining univariate statistical analysis of Pand FC values with multivariate statistical analysis of VIP values further screened out the differential ions between raw and processed PM.

2.4 Ultraperformance liquid chromatography-qqq-MS/MS analysis

2.4.1 Scheduled MRM method development

The scheduled MRM ion pairs were established based on the differential ions and secondary fragment ions of PM from the results of Section 2.3.2. Then, combined with the composition identification results of PM, the MRM ion pairs were further confirmed, and the proposed pseudotarget MRM method was constructed. This method was used to perform semiquantitative analysis in sample B, and the peak area data of the marker components were acquired.

The analysis of samples was performed using a Waters AcquityTM UPLC I-Class system equipped with a Xevo TQ-XS mass spectrometer (Waters, Milford, MA, United States). The chromatographic column and chromatographic separation conditions were the same as the conditions of the previous

No.	Compounds	Ion pair (m/z)	CV	CE
X1	Catechin	289.07 > 203.07	30	29
X2	Epicatechin	289.07 > 203.07	30	29
X3	Torachrysone-8- <i>O</i> -β-D-glucopyranoside	407.13 > 245.08	30	33
X4	7-acetyl-3,8-dihydroxy-6-methyl-1-naphthyl-β-D-glucopyranoside	393.12 > 231.06	30	33
X5	Epicatechin-3-O-gallate	441.08 > 289.07	30	34
X6	Emodin-8- <i>O</i> -β-D-glucopyranoside	431.1 > 269.04	30	34
X7	Emodin bianthrones	509.12 > 253.75	30	31
X8	Emodin-physcion bianthrones	523.14 > 253.83	30	30
X9	Physcion bianthrones	537.15 > 254.73	30	41
X10	$2,3,5,4'$ -tetrahydroxystilbene-2- O - β -D-(2- O -monogalloylesters)-glucopyranoside	557.13 > 243.06	30	30
X11	polygonibene E	581.16 > 243.06	30	30
X12	Polygonumnolides C1-C4	671.18 > 416.11	30	26
X13	Polygonumnolides A1-A4	685.19 > 416.11	30	26
X14	PM 14-17	757.17 > 458.12	30	31
X15	PM 22-25	933.24 > 458.12	30	33
X16	PM 5	919.23 > 458.12	30	33

TABLE 1 Optimized ion pairs and CV and CE parameters of 16 compounds.

UPLC-Q-TOF-MS method. The optimal MS conditions were as follows: capillary voltage at 2.5 kV under negative mode; source temperature at 150°C; desolvation gas temperature at 500°C; desolvation gas flow at 850 L/h; and cone gas flow at 150 L/h. Ion pairs and CV and CE parameters are detailed in Table 1.

The pseudotargeted MRM method was applied for semiquantitative comparison of PM samples (raw PM: S1-S30, processed PM: Z1-Z20).

2.4.2 Method validation

The developed UPLC-MS/MS method was validated with sample Z-1 as an example in terms of specificity, repeatability, precision, linearity, and stability. Specificity was evaluated by comparing samples with the negative control. Repeatability evaluation was carried out by analyzing six replicate samples independently. Precision was investigated by six consecutive injections of the same sample. Linearity was constructed by fitting the peak area of each compound under the injection of 0.5, 1, 1.5, 2, 2.5, and 3 μ l of one sample. The same sample was injected at 0, 6, 12, 24, and 30 h to verify the stability. The relative standard deviation (RSD) of the peak area of the characteristic peaks was used to evaluate the results.

2.5 Hepatotoxicity assay in vitro

Two types of hepatocytes, L02 and HepG2, were used to assess the hepatotoxicity of PM extract *in vitro*. L02 and HepG2 cells were inoculated in 384-well cell plates (density:

HepG2 1,000 cells/well; L02 800 cells/well) with 40 μ l of cell suspension per well and were incubated overnight at 37°C in a 5% CO₂ incubator. HepG2 cells were cultured in DMEM containing 10% FBS and 100 U/mL penicillin and streptomycin, while L02 cells were cultured in RPMI 1640 medium. On the day of the experiment, 10 μ l of compound working solution (sample B, PM extracting solution of 0.064, 0.32, 1.6, 8, 40, 200, and 1,000 μ g/ml) was added to each well according to the experimental requirements, and this was cultivated at 37°C for 72 h with 5% CO₂ shielded from light. At the end of the incubation, 5 μ l of CCK8 reagent was added to the cell plates, and this were incubated for 4 h with 5% CO₂ at 37°C. The absorbance at 450 nm was measured, and the inhibition rate was calculated according to the following equation:

Inhibition ratio (%) = $(OD_S - OD_{NC})/(OD_{STSP} - OD_{NC})$

\times 100%

where OD_S stands for the absorbance of the working solution (cell + medium + compound to be tested); OD_{NC} stands for the absorbance of the negative control (cell + medium + DMSO); and OD_{STSP} stands for the absorbance of the positive control (cell + medium + 10 μ M STSP).

According to the inhibition ratios of the compounds, the IC_{50} values (the concentration corresponding to 50% of the maximum inhibition response) were calculated from the dose-response curves using GraphPad Prism 9.0. The experiment was performed three times in parallel, and finally, the mean IC_{50} value was obtained for each sample.

2.6 Spectrum-effect relationship analysis

2.6.1 Gray relational analysis

GRA is a method to determine the degree of association between factors based on the similarity of the geometry of the change curves in each factor. As a simple and effective method, GRA has been widely used in the evaluation of spectrum-effect relationship in TCM (Wang et al., 2018; Ma et al., 2020). In this study, the peak area of each feature was taken as the comparison series, and the $1/\mathrm{IC}_{50}$ value of the cytotoxicity assessment index was defined as the reference series (all the original data were dimensionless and processed before analysis). The correlation coefficients between the reference series values and each comparison series were calculated, and the average value of the gray correlation coefficient was obtained, which was the gray correlation degree. The influence degree of each characteristic variable on hepatocyte toxicity was evaluated by comparing the gray correlation degrees.

2.6.2 Orthogonal partial least squares analysis

OPLS, a special type of multiple linear regression model, was used to find the relationship between two matrices X and Y by considering orthogonal signal correction based on partial least squares regression (Liang et al., 2017; Liao et al., 2020). In this study, an OPLS model was constructed to characterize the correlation between the hepatotoxicity index IC_{50} and the chemical peaks. The peak area of each characteristic ion was used as the independent variable X, and the IC_{50} value was used as the dependent variable Y. In SIMCA 14.0.1 (Umetrics AB, Umea, Sweden), the VIP and regression coefficients were used to find the main characteristic components that were significantly correlated with hepatotoxicity.

2.6.3 Back propagation artificial neural network analysis

The BP-ANN algorithm is a nonlinear mathematical model based on the structure of neural synaptic connections in the brain. The BP neural network is a kind of multilayer feedforward neural network trained by the error back propagation algorithm and has been one of the most widely used neural network models (Jiang et al., 2018; Shi et al., 2018). The BP neural network can connect the input and output parameters and can continuously modify the weights and biases of each layer through iterative learning to minimize the overall error of the output layer. To screen representative hepatotoxic components from different perspectives, we used MATLAB R2019b (Mathworks, Natick, NJ, United States) to build the BP-ANN model for the association of chromatographic peaks with hepatotoxicity IC₅₀. The BP neural network was established using the characteristic peak area as the input layer neuron, the IC50 value as the output layer neuron, the hidden layer of one layer, and the hidden layer node number optimization as 10. Moreover, two parameters were

used to evaluate the importance of the variables in the neural network.

MIV was considered to be one of the best indices for evaluating the correlation of variables in the neural network (Xu et al., 2013). The sign of the MIV value represents the direction of the correlation, and the absolute value reflects the importance of the impact. Sensitivity analysis was another important method for evaluating the connection weights in ANN models (Wang et al., 2017; Qiao et al., 2021). The contribution ratios of the characteristic peaks to the cytotoxicity index IC₅₀ were calculated by connection weights. The Garson equation was applied to show the relative influence of the independent variables on the dependent variable. The equation was as follows:

$$P_{\rm ac} = \frac{\sum_{b=1}^{N} \left(\frac{|w_{ab}|}{\sum_{d=1}^{M} |w_{dj}|} |e_{b\nu}| \right)}{\sum_{a=1}^{M} \left(\sum_{b=1}^{N} \left(\frac{|w_{ab}|}{\sum_{d=1}^{M} |w_{dj}|} |e_{b\nu}| \right) \right)}$$

where *P* stands for the percentage influence of input neurons, w indicates the weight between input and hidden neurons, *e* indicates the weight between hidden and output neurons, *M* indicates the number of input neurons, *N* indicates the number of hidden neurons, and v indicates the number of output neurons.

3 Results

3.1 Characterization of chemical components in *Polygonum multiflorum*

Based on the literature summary and self-built compound library, the main components of PM are stilbenes and anthraquinones. In addition, PM includes flavonoids, lignans, dianthrones, phospholipids, and polysaccharides. Comparing the negative ion response with the positive ion response, the negative ion mode had more peaks and a much stronger response, so negative ion scan was selected for detection (Supplementary Figure S1). Moreover, the peak profiles of PM between raw and processed PM were basically consistent (Supplementary Figure S2), indicating that processing does not change the types of compounds in PM but the relative content of compounds. Considering the differences in the chemical composition of PM from different batches and origins, a mixed sample was chosen for qualitative analysis. The chromatographic column, mobile phase, elution conditions, and MS conditions were further optimized. A total of 112 components were detected and preliminarily identified through self-built database matching, comparison with standard products and the literature, and fragment ion deduction (Table 2). These tentative compounds could be classified into four types according to the structural

No	Observed RT (min)	Molecular formula	Component name	Observed m/z	Expected <i>m/z</i>	Mass error (ppm)	Fragment
ld	1.03	$C_4H_6O_4$	Butanedioic acid	117.0190	117.0193	-3.22	71.0138; 59.0137; 55.0187
2d	1.05	$C_6H_8O_4$	2,3-di-hydro-3,5-dihydroxy-6-methyl-4(<i>H</i>)- pyran-4-one	143.0350	143.0349	0.12	129.0187; 96.9687; 114.0557; 78.9591
3d	1.20	$C_7H_6O_5$	Gallic acid	169.0147	169.0142	2.44	125.0246; 96.9687; 110.0254
d	1.41	$C_{13}H_{16}O_{10}$	Gallic acid-O-glucoside	331.0654	331.0665	-3.32	169.0107; 125.0221
d	1.53	$C_6H_{13}NO_2$	Leucine	130.0871	130.0868	2.31	88.0363; 85.0303
d	2.25	$C_6H_8O_7$	Citric acid	191.0201	191.0197	2.05	128.0355; 111.0086; 87.0088; 85.0294
d	2.45	$C_{15}H_{14}O_7$	Gallocatechin	305.0673	305.0666	2.09	213.1246; 241.0027; 125.0245; 96.9604
d	3.16	$C_{13}H_{16}O_9$	Protocatechuic acid-O-glucoside	315.0697	315.0716	-6.03	153.0177; 195.0297; 111.0094
d	3.82	$C_{11}H_9NO_2$	2-vinyl-1H-indole-3-carboxylic acid	186.0545	186.0555	-5.37	142.0658
0c	4.07	$C_{30}H_{26}O_{12}$	Procyanidin B	577.1358	577.1351	1.10	289.0716; 559.1279; 451.1047; 407.0772; 125.0243
1c	4.22	$C_{15}H_{10}O_7$	Quercetin	301.0355	301.0354	0.56	257.0455; 125.0243 285.0397; 179.0243
2c	4.88	$C_{15}H_{14}O_{6}$	Catechin	289.0721	289.0717	1.02	271.0553; 245.0812 137.0244; 123.0450
3d	5.24	$C_8H_8O_4$	Vanillic acid	167.0351	167.0344	4.19	137.0259; 123.0426
4d	5.83	$C_7H_6O_2$	P-hydroxybenzaldehyde	121.0296	121.0295	0.99	93.0341
5b	6.54	$C_{21}H_{22}O_{11}$	Rumejaposide D	449.1088	449.1089	-0.15	259.0612; 255.0660; 125.0242; 407.0769; 368.0900
6d	7.31	$C_{11}H_{10}O_3$	Altechromone A	189.0560	189.0557	1.51	147.0448; 124.0157
7c	7.92	$C_{15}H_{14}O_{6}$	Epicatechin	289.0718	289.0717	0.28	243.0660; 125.0244
8c	8.03	$C_{37}H_{30}O_{16}$	3-O-galloyl-procyanidin B2	729.1465	729.1461	0.54	499.1267; 589.1452 247.0619; 243.0660 125.0244
9b	8.58	$C_{14}H_{18}O_{10}$	2,3,4,6-tetrahy-droxyacetophenone-3- O - β -D-glucoside	345.0832	345.0827	1.44	182.0225; 242.0577 287.0560; 125.0246 96.9606
0c	8.67	$C_{30}H_{26}O_{12}\\$	Isomer-Procyanidin B	577.1351	577.1351	-0.12	439.1056; 289.0715 345.0818; 182.0225
1b	9.12	$C_{26}H_{32}O_{14} \\$	Isomer-2,3,5,4′-tetrahydroxystilbene-2,3-di- O-β-D-glucopyranoside	567.1719	567.1719	0.01	405.1186; 387.1069 241.0503; 281.0445
2d	9.61	$C_{17}H_{20}O_9$	7-hydroxy-3,4-dimethylcoumarin-5- <i>O-β-</i> D- glucopyranoside	367.1029	367.1034	-1.45	243.0665; 225.0554 109.0293
3b	9.61	$C_{20}H_{22}O_9$	<i>Cis-</i> 2,3,5,4′-tetrahydroxystilbene-2- <i>O-β</i> -D- glucoyranoside	405.1193	405.1191	0.52	243.0665; 189.0560 137.0245; 93.0344
4c	10.01	$C_{35}H_{34}O_{15}$	Polygonflavanol A	693.1821	693.1825	-0.61	549.1604; 287.0560 259.0612; 125.0244 241.0504
5a	10.91	$C_{15}H_{12}O_4$	Emodin anthrone	255.0660	255.0662	-1.29	137.0241; 109.0288 93.0345
6a	10.92	$C_{22}H_{26}O_8$	1,3-dihydroxy-6,7-dimethylxanthone-1- <i>Ο-β-</i> D-glucopyranoside	417.1184	417.1555	-1.75	259.0609; 255.0659 109.0288; 137.0242
7a	11.08	$C_{20}H_{22}O_{10}$	6-methoxyl-2-acetyl-3-methyl-1,4- naphthoquinone-8- <i>Ο-β</i> -D-glucopyranoside	421.1137	421.1140	-0.73	407.0767; 259.0610 255.0660; 213.0555

No	Observed RT (min)	Molecular formula	Component name	Observed m/z	Expected <i>m/z</i>	Mass error (ppm)	Fragment
28c	11.11	$C_{44}H_{34}O_{20}$	3,3'-di-O-galloyl-procyanidin B2	881.1582	881.1571	1.24	729.1451; 513.1201; 407.0767; 273.0391
29a	11.18	$C_{16}H_{10}O_7$	Carboxyl emodin	313.0344	313.0348	-1.28	269.0433; 243.0634; 169.0107
30c	11.65	$C_{22}H_{18}O_{10}$	Epicatechin-3-O-gallate	441.0828	441.0827	0.16	289.0714; 169.0145; 125.0245
31c	11.75	$C_{15}H_{10}O_6$	Kaempferol	285.0402	285.0404	-1.08	193.0142; 125.0245
32d	11.89	$C_{28}H_{38}O_{13}$	(+)-lyoniresinol-3- O - β -D-glucopyranoside	581.2239	581.2240	-0.15	549.1606; 521.1300; 387.1072; 253.0081
33b	12.22	$C_{22}H_{24}O_{10}$	2,3,5,4′-tetrahydroxystilbene-2-O-(6- O-acetyl)-β-D-glucopyranoside	447.1288	447.1296	-1.88	259.0608; 227.0713; 185.0608
4b	12.70	$C_{26}H_{32}O_{14}$	2,3,5,4′-tetrahydroxystilbene-2,3-di- <i>O-β</i> -D- glucopyranoside	567.1724	567.1719	0.84	405.1179; 269.0455; 243.0664; 225.0553
35a	13.16	$C_{16}H_{12}O_{6}$	Fallacinol	299.0558	299.0561	-1.15	286.0480; 253.0495; 161.0243; 179.0354
6b	13.21	$C_{26}H_{34}O_{11}$	β-D-glucoside,4-[2,3-dihydro-3- (hydroxymethyl)-5-(3-hydroxypropyl)-7- methoxy-2-yl]-2-methoxypheny	521.2054	521.2023	5.95	359.1455; 313.1039; 243.0634
37a	13.26	$C_{21}H_{22}O_{11}$	Isomer-rumejaposide D	449.1090	449.1089	0.19	379.0815; 169.0145; 165.0558; 286.0480
8b	13.51	$\rm C_{60}H_{66}O_{27}$	Multiflorumiside L/K	1,217.3710	1,217.3718	-0.68	811.2458; 646.1675; 243.0665; 405.1189
9b	13.52	$C_{20}H_{22}O_9$	<i>Trans</i> -2,3,5,4′-tetrahydroxystilbene-2- <i>O</i> -β- D-glucopyranoside	405.1191	405.1191	-0.08	243.0665; 225.0554 109.0293; 215.0713
0a	14.08	$C_{47}H_{46}O_{22}$	PM 12-13	961.2381	961.2408	-2.79	693.1812; 503.1164; 555.1137; 393.0609; 839.2375
1b	14.47	$C_{19}H_{20}O_8$	2,3,5,4′-tetrahydroxystilbene-2-O-β-D- xyloside	375.1080	375.1085	-1.54	243.0665; 225.0553 109.0291
2Ь	14.61	$C_{27}H_{26}O_{13}$	2,3,5,4'-tetrahydroxystilbene-2-Ο-β-D-(2- O-monogalloyl esters)-glucopyranoside	557.1310	557.1301	1.70	243.0666; 241.0504 313.0567; 405.1189 125.0243
3c	15.54	$C_{21}H_{20}O_{12} \\$	Quercetin 3- β -D-glucopyranoside	463.0860	463.0882	-4.81	405.1171; 303.0514 379.0815; 269.0456
4c	15.60	$C_{15}H_{12}O_7$	Dihydroquercetin	303.0477	303.0505	-9.24	153.0177; 125.0221
5d	15.84	$C_{17}H_{17}NO_4$	Trans-N-caffeoyltyramine	298.1084	298.1084	-0.28	169.0836; 227.0710; 135.0450
6b	16.45	$C_{27}H_{26}O_{13}$	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-(3- O-monogalloyl esters)-glucopyranoside	557.1310	557.1301	1.77	243.0664; 313.0567 405.1180; 467.1097 125.0244
!7b	16.59	$C_{27}H_{26}O_{12}$	2,3,5,4'-tetrahydroxystilbene-2-O-β-D-(2"- O-galloyl)-glucopyranoside	541.1355	541.1352	0.65	243.0664; 313.0567; 169.0145; 405.1180; 467.1097
8b	16.82	$C_{14}H_{12}O_3$	Resveratrol	227.0716	227.0713	1.04	181.0648; 143.0502; 135.0446; 117.0344
9b	17.53	$C_{27}H_{26}O_{12}$	β -Glucopyranoside, 3-hydroxy-5-[(1 <i>E</i>)-2-(4-hydroxyphenyl)ethenyl]phenyl, 2-(3,4,5-trihydroxybenzoate)	541.1351	541.1352	-0.05	485.1242; 313.0564; 169.0145
0d	18.00	$C_{19}H_{22}O_{9}$	7-acetyl-3,8-dihydroxy-6-methyl-1- naphthyl-β-D-glucopyranoside	393.1190	393.1191	-0.24	273.0767; 231.0665; 295.0583; 161.0245
1b	18.47	$C_{22}H_{24}O_{10}$	Polygonibene D	447.1292	447.1296	-1.06	255.0660; 243.0664 241.0502
52c	19.63	$C_{23}H_{24}O_{12}$	Tricin 7-O-β-D-glucoside	491.1191	491.1195	-0.74	

No	Observed RT (min)	Molecular formula	Component name	Observed m/z	Expected <i>m/z</i>	Mass error (ppm)	Fragment
							269.0451; 313.0553 148.0526; 355.0447 439.0652
53d	19.75	C ₁₈ H ₁₉ NO ₄	N-trans-feruloyltyramine	312.1240	312.1241	-0.29	274.0120; 269.0451 178.0516; 148.0526 123.0452
4a	19.94	$C_{22}H_{26}O_{10}$	Torachrysone-8- <i>O</i> -(6′-O-acetyl)-β-D- glucopyranoside	449.1447	449.1453	-1.39	393.0615; 274.0120 245.0815; 230.0584 349.0699
5b	20.13	$C_{29}H_{28}O_{12}$	Tetrahydroxystilbene-O-(caffeoyl)- glucopyranoside	567.1498	567.1503	-0.88	243.0634; 405.1207
6b	20.40	C20H22O8	Polydatin	389.1237	389.1242	-1.19	283.0608; 227.0711
7d	20.50	$C_{19}H_{21}NO_5$	N-trans-feruloyl-3-methyldopamine	342.1341	342.1347	-1.61	313.0546; 227.0711 255.0656; 148.0524
8b	20.75	$C_{21}H_{24}O_8$	Desoxyrhaponticin	403.1392	403.1398	-1.62	349.0708; 269.0453 225.0552; 151.0037
i9b	21.65	$C_{30}H_{30}O_{12}$	Polygonibene G	581.1662	581.1665	-0.39	419.1125; 295.0600 389.1015; 125.0244
0a	21.85	$C_{21}H_{20}O_{10}$	Aloe-emodin-3-(hydroxymethyl)- <i>O-β-</i> D- glucopyranoside	431.0987	431.0983	0.70	240.0428; 325.0707 268.0372; 299.0561
1a	22.11	$C_{23}H_{22}O_{11}$	Emodin-8-O-(6'-O-acetyl)-β-D- glucopyranoside	473.1093	473.1089	0.88	269.0459; 225.0558
2b	22.60	$C_{29}H_{28}O_{11}$	2,3,5,4′-tetrahydroxystilbene-2- <i>O</i> -β-D-(2″- O-coumaroyl)-glucoside	551.1545	551.1553	-1.45	389.1003; 241.9957 405.1207
3b	22.90	$C_{30}H_{30}O_{12} \\$	Polygonibene E	581.1669	581.1665	0.83	405.1184; 243.0663 256.0375
4a	22.95	$C_{25}H_{32}O_{13}$	Polygonimitin E	539.1765	539.1770	-0.91	405.1184; 243.0663 256.0375; 489.1212 175.0400
5d	23.09	$C_{36}H_{36}N_{2}O_{8}$	Cannabisin D	623.2389	623.2399	-1.66	389.1026; 245.0814 225.0555
6a	23.73	$C_{20}H_{24}O_9$	Torachrysone-8- O - β -D-glucopyranoside	407.1346	407.1347	-0.39	245.0820; 230.0587 215.0352
7a	24.05	$C_{16}H_{12}O_{6}$	Citreorosein-8-methyl ether	299.0556	299.0561	-1.80	255.0656; 243.0660 213.0552; 160.0162
8a	24.74	$C_{16}H_{12}O_5$	Emodin-8-methyl ether	283.0611	283.0612	-0.51	240.0426; 175.0400 145.0296
9c	24.96	$C_{21}H_{20}O_{11}$	Quercetin-3-O-rhamnoside	447.0931	447.0933	-0.45	285.0399; 313.0546 337.0788; 361.0725 245.0810
0a	25.40	$C_{15}H_{10}O_5$	Isomer-emodin	269.0458	269.0455	0.26	93.03439; 185.0607
1a	25.62	$C_{21}H_{20}O_{10}$	Emodin-8- O - β -D-glucopyranoside	431.0985	431.0983	0.34	269.0459; 225.0559
2a	26.09	$C_{45}H_{44}O_{21}$	PM 5	919.2315	919.2302	1.35	875.2393; 713.1859 458.1210; 416.1108
3a	27.03	$C_{45}H_{44}O_{21}$	Isomer-PM 5	919.2303	919.2302	0.07	875.2387; 713.1860 458.1215
4d	27.22	$C_{36}H_{36}N_{2}O_{8} \\$	(+)-Grossamide	623.2395	623.2399	-0.57	269.0458; 243.0660 416.1106
′5c	27.32	$C_{17}H_{14}O_7$	Tricin	329.0660	329.0666	-2.13	243.0660; 313.0484 161.0246; 254.0583
'6a	27.72	$C_{22}H_{22}O_{10}$	Physcion-1- O - β -D-glucopyranoside	445.1135	445.1140	-1.15	283.0611; 240.0426 145.0295; 387.0501
7a	28.11	C15H10O6	Citreorosein	285.0410	285.0404	1.78	

No	Observed RT (min)	Molecular formula	Component name	Observed m/z	Expected <i>m/z</i>	Mass error (ppm)	Fragment
							257.0455; 241.0503; 224.0477; 195.0452; 183.0452
78a	28.46	$C_{17}H_{14}O_5$	1,6-dimethyl ether-emodin	297.0765	297.0768	-1.06	283.0612; 269.0458; 240.0428
79a	28.51	$C_{22}H_{22}O_{10}$	Physcion-8- O - β -D-glucopyranoside	445.1138	445.1140	-0.40	283.0612; 240.0428; 225.0552; 148.0529
80a	28.80	$C_{22}H_{26}O_{10}$	Isomer-torachrysone-8-Ο-(6′-Ο-acetyl)-β-D- glucopyranoside	449.1450	449.1453	-0.66	255.0658; 245.0815; 230.0584; 359.0909; 159.0445
81a	29.00	$C_{21} {\rm H}_{20} O_{11}$	Citreorosein-O-glucoside	447.0931	447.0933	-0.50	243.0659; 211.1340; 329.2333; 125.0245
32a	30.92	C16H12O5	Isomer-physcion	283.0611	283.0612	-0.39	269.0454; 239.0326
83a	31.52	$C_{45}H_{46}O_{19}$	PM 26-27	889.2553	889.2561	-0.80	847.2462; 701.1841; 458.1212; 416.1108; 254.0580
84a	33.16	$C_{17}H_{12}O_6$	2-Acetyl-emodin	311.0562	311.0561	0.15	283.0606; 269.0457; 240.0429
85a	33.40	$C_{37}H_{34}O_{13}$	Polygonumnolide E	685.1922	685.1927	-0.73	671.1752; 416.1109; 309.1735; 254.0586
36a	34.64	$C_{15}H_{10}O_4$	Chrysophanol	253.0498	253.05	-1.19	225.0545
87a	34.74	$C_{15}H_{10}O_5$	Emodin	269.0459	269.0455	1.32	225.0560; 241.0505; 197.0608
8a	36.87	$C_{30}H_{22}O_8$	Trans/cis-emodin dianthrones	509.1245	509.1242	0.58	254.0582; 225.0545
19a	37.13	$C_{15}H_{10}O_{6}$	Lunatin	285.0404	285.0404	-0.26	269.0457; 241.0501; 199.1704
90a	37.17	$C_{16}H_{12}O_5$	Physcion	283.0609	283.0612	-0.96	269.0456; 256.0362; 240.0422
91a	38.69	$C_{31}H_{24}O_8$	Trans/cis-emodin-physcion dianthrones	523.1395	523.1398	-0.68	254.0583
92a	40.37	$C_{32}H_{26}O_8$	Trans/cis-physcion dianthrones	537.1541	537.1555	-2.60	243.0661; 437.3076; 339.1998
93d	41.55	$C_{16}H_{32}O_2$	Tetradecanoic acid ethyl ester	255.2333	255.2329	1.31	205.1602; 96.9602
94d	42.22	$C_{17}H_{34}O_2$	Hexadecanoic acid methyl ester	269.2485	269.2486	-0.47	177.9736; 129.9760; 221.0857
95d	42.92	$C_{18}H_{36}O_2$	Hexadecanoic acid ethyl ester	283.2645	283.2642	0.75	183.0122; 99.0194; 163.1127
96d	43.13	$C_{20}H_{38}O_2$	Ethyl oleate	309.2796	309.2799	-1.11	163.1127; 177.1283; 223.0358; 227.2015
97d	43.47	$C_{19}H_{38}O2$	Octadecanoic acid methyl ester	297.2796	297.2799	-0.89	241.0502; 119.9469
98d	44.01	$C_{20}H_{40}O_2$	Octadecanoic acid ethyl ester	311.2956	311.2955	0.15	229.1596; 163.1130; 130.9451
9Ъ	12.37; 13.19	$C_{41}H_{46}O_{19}$	(unknown) Dimer of stilbene glycoside	841.2562	841.2561	0.12	647.1770; 485.1239; 259.0608; 227.0713; 125.0243
100b	15.12; 16.18; 17.64; 18.56	$C_{40}H_{42}O_{18}$	(Isomer) Multiflorumiside A1/B1	809.2308	809.2298	1.15	647.1773; 719.1815; 485.1239; 467.1109; 267.0651
101b	19.90; 20.67	$C_{27}H_{24}O_{13}$	Polygonumoside A/B	555.1154	555.1144	1.86	393.0615; 274.0120; 245.0815; 230.0584; 349.0699
102b	21.48; 22.52	$C_{40}H_{42}O_{18}$	Polygonibene A/B/C	809.2295	809.2298	-0.44	647.1766; 485.1236; 255.0657; 405.1174; 125.0244

No	Observed RT (min)	Molecular formula	Component name	Observed m/z	Expected m/z	Mass error (ppm)	Fragment
103a	24.52; 29.27	$C_{23}H_{22}O_{11}$	Isomer-emodin-8-O-(6'-O-acetyl)-β-D- glucopyranoside	473.1091	473.1089	0.26	269.0454; 225.0552; 167.0349
104a	25.27; 26.92; 27.67; 28.47	$C_{46}H_{46}O_{21}$	PM 22-25	933.2457	933.2459	-0.15	889.2548; 809.2265; 703.1669; 458.1210; 283.0611
105a	27.37; 30.01	$C_{42}H_{42}O_{18}$	PM 1-4	833.2306	833.2298	0.90	671.1764; 431.0980; 416.1110; 175.0398; 254.0583
106a	28.64; 29.77; 30.41	$C_{39}H_{34}O_{16}$	PM 14-17	757.1769	757.1774	-0.68	713.1868; 458.1210; 269.0458; 225.0552
107a	29.52; 30.89; 31.57	$C_{43}H_{44}O_{18}$	Polygonumnolides B1-B3	847.2463	847.2455	0.99	707.1738; 685.1909; 416.1108; 283.0607; 240.0428
108a	30.86; 31.06; 31.24; 31.49	$C_{40}H_{36}O_{16}$	PM 30-33	771.1927	771.1931	-0.51	458.1212; 398.0987; 416.1109; 285.0400; 254.0580
109a	32.04; 32.27; 33.51; 33.99	$C_{36}H_{32}O_{13}$	Polygonumnolides C1-C4	671.1775	671.1770	0.76	265.1480; 458.1207; 553.1048; 416.1111; 254.0586
110a	33.41; 33.72; 34.76; 34.92	$C_{37}H_{34}O_{13}$	Polygonumnolides A1-A4	685.1931	685.1927	0.66	671.1752; 416.1109; 309.1735; 254.0586
111b	4.58; 5.69; 6.57; 8.04	$C_{40}H_{44}O_{19}$	(Isomer) Polygonumoside C/D	827.2403	827.2404	-0.07	665.1867; 467.1116; 269.0455; 225.0542; 131.0827
112b	5.91; 10.32; 10.38; 12.75; 13.50	$C_{40}H_{44}O_{18}$	Multiflorumiside A-I	811.2442	811.2455	-1.64	649.1914; 487.1372; 405.1182; 243.0662; 225.0553

a: Anthraquinones and derivatives. b: Stilbenes and derivatives. c: Flavonoids and derivatives. d: Others. The names of PM 1-4, PM 5, PM 14-17, PM 22-25, and PM 26-27 were from Yang, J. B. (2019). Journal of pharmaceutical and biomedical analysis, 172, 149-166.

characteristics, including 43 anthraquinones, 28 stilbene glycosides, 15 flavonoids, and 26 others.

3.2 Metabolomics analysis of raw and processed *Polygonum multiflorum*

The clinical use of PM usually includes both raw and processed PM. Previous studies have shown that the chemical composition of processed PM may change compared with that of raw PM, which may lead to a change in the pharmacological effects. For a fact, various studies have also shown that the toxicity of PM was significantly reduced after processing, which may be due to the significant reduction of toxic ingredients. To date, few studies have been performed to fully clarify the compositional changes in PM after treatment. Here, UPLC-Q-TOF-MS analysis combined with multivariate statistical analysis was used to distinguish between raw and processed PM. The PCA graph shows that the QC samples were closely clustered, indicating that the LC-MS analysis system was credibly reproducible and stable during the testing period. As seen from the PCA plots (Supplementary Figure S3), the raw PM and manufactured PM samples were able to be obviously separated and gathered separately. To further screen out the latent variables for distinguishing between raw and processed PM, OPLS-DA analysis was performed. The R2Y and Q2 of the OPLS-DA model were 0.98 and 0.92, respectively, which indicated excellent fitness and reliability. From the results (Figure 2), it was evident that the raw and processed PM were significantly differentiated under the supervised model. There was no overfitting in the OPLS-DA model by 200times permutation tests, as shown in Figure 2. Furthermore, with VIP > 1.5, univariate statistical analysis p < 0.5, and fold change < 0.5, 126 differential characteristic ions were screened for significant reduction after preparing PM. Combined with the results of the abovementioned component analysis, 13 potential compounds were identified after excluding the interfering fragments and confirming the molecular ions. The results are shown in Table 3.



Orthogonal partial least squares analysis-DA score chart and permutation test analysis of *Polygonum multiflorum* (PM) samples (S: raw PM; Z: processed PM).

TABLE 3 Detailed information of 13 different compounds between raw and processed Polygonum multiflorum .

Compounds	Rt- m/z (Da)	VIP	<i>p</i> -value	FC-value
Catechin	4.88_289.0716	11.03	$1.50E^{-6}$	0.286
Epicatechin	7.89_290.0786n	4.08	$4.60E^{-4}$	0.397
Torachrysone-8-Ο-β-D-glucopyranoside	23.71_408.1413n	9.99	$1.00E^{-9}$	0.225
7-acetyl-3,8-dihydroxy-6-methyl-1-naphthyl-β-D-glucopyranoside	17.97_393.1173	3.48	$2.42E^{-10}$	0.137
Epicatechin-3-O-gallate	11.59_442.0917n	7.44	9.32E ⁻⁵	0.328
Emodin-8-O-β-D-glucopyranoside	25.61_431.2031	2.47	$1.75E^{-8}$	0.441
2,3,5,4'-tetrahydroxystilbene-2-O- β -D-(2-O-monogalloylesters)-glucopyranoside	14.58_558.1371n	13.36	5.97E ⁻⁵	0.359
polygonibene E	22.91_582.1726n	5.56	$2.50E^{-7}$	0.366
Polygonumnolides C1-C4	32.40_671.1733	1.83	$5.55E^{-3}$	0.380
Polygonumnolides A1-A4	34.95_685.1887	2.06	$3.15E^{-3}$	0.366
PM 14-17	30.37_758.1799n	1.59	$2.04E^{-3}$	0.157
PM 22-25	27.64_933.2410	1.86	$7.60E^{-5}$	0.186
PM 5	27.10_920.2342n	1.77	$1.23E^{-4}$	0.180

3.3 Pseudotargeted spectrum construction of discriminant metabolites

In MRM-based absolute quantification, calibration curves were often drawn for real compounds based on the conversion of the corresponding peak area into the content. However, absolute quantification usually cannot be achieved owing to the limitations of the standards, and the relative content between different groups can be compared by peak area. In consideration of the potential toxic dianthrone components identified in our previous studies and dianthrone aglycon hydrolyzed in acidic gastric juice *in vivo*, three nuclear parents of dianthrones were summarized (Li et al., 2020; Wang et al., 2021; Yang et al., 2021). Combined with the 13 differential metabolites obtained from the metabonomics analysis, UPLC-qqq-MS/ MS semiquantitative profiles were further established. By optimizing the MRM ion pair and CV and CE values, semiquantitative mass spectra of the 16 compounds were constructed. The results are listed below. This method was successfully applied to 30 batches of raw PM and 20 batches of processed PM, and the standardized peak area heatmap is shown in Figure 3.

At last, a methodological investigation on the established scheduled MRM method, including specificity, linearity, precision, repeatability, and stability, was conducted. The





Compound	GRA (correla	ation)	OPLS (R value)		
	L02	HepG2	L02	HepG2	
X1	0.763	0.754	0.873	0.478	
X2	0.818	0.778	-0.285	0.061	
X3	0.806	0.813	0.193	-0.055	
X4	0.804	0.816	-0.062	-0.150	
X5	0.825	0.814	-0.515	-0.510	
X6	0.826	0.776	-0.387	-0.210	
X7	0.755	0.718	-0.443	-0.222	
X8	0.750	0.707	0.160	0.070	
Х9	0.718	0.681	-0.101	-0.190	
X10	0.800	0.776	-0.266	-0.318	
X11	0.786	0.769	-0.191	-0.062	
X12	0.733	0.715	0.504	0.506	
X13	0.744	0.755	0.239	0.198	
X14	0.772	0.779	-0.597	-0.440	
X15	0.750	0.774	0.048	-0.121	
X16	0.755	0.775	-0.272	-0.252	

TABLE 4 Correlation degree between peak areas of 16 targeted compounds and hepatotoxicity.

16 target compounds showed great specificity (Supplementary Figure S4). Among the 16 target analytes, linearity was good in the range of 0.5–3 μ l injection with R > 0.98. Precision and repeatability results showed that the RSD values of all 16 compounds were less than 15%. For stability within 30 h, the RSD values ranged between 1.53% and 14.7% for all components.

3.4 Hepatotoxicity evaluation of *Polygonum multiflorum*

It is necessary to evaluate hepatotoxicity *in vitro*, but sometimes a cellular model does not provide an accurate and comprehensive assessment of the hepatotoxicity of TCM. In this study, two commonly used hepatocyte models were chosen, L02 and HepG2, to comprehensively estimate the hepatotoxicity of raw and processed PM extracts. The IC₅₀ values for the raw and processed PM are shown in **Supplementary** Table S3. From Figure 4, the mean IC₅₀ values of PM in both types of hepatocytes increased significantly after processing (p < 0.0001, ****), indicating the basic theories of processing detoxification. In specific, 30 batches of raw PM had an average IC₅₀ value of 250 µg/ mL in L02 cells and 281 µg/mL in HepG2 cells. However, 20 batches of processed PM had an average IC₅₀ value of 735 µg/ml in L02 cells and 1,185 µg/ml in HepG2 cells.

3.5 Results of spectrum–effect relationship

3.5.1 Gray relational analysis results

The relationship between chromatographic peaks and hepatotoxicity effect was established by the GRA model. The degree of correlation between each chromatographic peak and hepatocyte toxicity is detailed in Table 4. The results showed that the gray relational degree between all 16 chromatographic peaks and the 1/IC₅₀ of L02 cells was between 0.718 and 0.826. The correlation between the 16 peaks and the 1/IC₅₀ of HepG2 cells was between 0.618 and 0.816. These results indicated that the 16 chromatographic peaks were closely correlated with hepatocyte toxicity. In total, dianthrone components X7, X8, X9, X12, X13, X14, X15, and X16; anthraquinone glycoside components X3, X4, and X6; stilbene glycosides X10 and X11; and flavanol compounds X1, X2, and X5 were all associated with hepatotoxicity in hepatocytes, which may synergistically contribute to the hepatotoxicity of PM.

3.5.2 Orthogonal partial least squares analysis results

OPLS analysis was conducted using an orthogonalized multiple linear regression model. In this study, an OPLS model was built to analyze the correlation between the chromatographic peaks of 16 compounds and the IC₅₀ of L02 and HepG2 hepatocytes (Figure 5). For L02 hepatocytes, the constructed model parameters R2X, R2Y, and Q2 were 0.94, 0.82, and 0.67, respectively. The permutation test was performed without overfitting. The results showed that the VIP values of all compounds were greater than 0.7. Combined with the correlation coefficient of less than 0.1, compounds X14, X5, X6, X7, X9, X2, X16, X10, and X11 were screened out. For HepG2 hepatocytes, the model parameters of R2X, R2Y, and Q2 were 0.93, 0.83, and 0.68, respectively, and the model had no overfitting. X5, X14, X10, X16, X7, X6, X9, X4, and X15 were highlighted with correlation coefficients less than -0.1 and VIP values greater than 0.7. For further analysis, the common significant components screened by both models were dianthrone components X7, X9, X14, and X16; anthraquinone glycoside X6; stilbene glycoside X10; and flavanol X5. These components may be of more prominent importance in the multicomponent synergistic hepatotoxicity of PM.

3.5.3 Back propagation artificial neural network results

BP-ANN is a multilayer network that uses an error back propagation algorithm for constant adjustment of weights. In this experiment, a simple 3-layer BP-ANN neural network was modeled with an input layer, one hidden layer, and an output



layer. The fitting degree of the model was evaluated using the mean square error (MSE) and regression R value. In the model, 80% of the random sample data were taken as the training set, and 20% of the sample data were used as the validation set. The results (Figure 6) demonstrated that for L02 cells, the established neural network model, where the R of the training and validation datasets reached 0.9380 and 0.9722, the MSE of the training and validation datasets reached 0.006 and 0.0027, respectively. For HepG2 cells, the R and MSE of

the training and validation datasets on the model were 0.9555 and 0.9559, 0.0068 and 0.0125, respectively.

As a result of the sensitivity analysis, the 16 compounds all had relatively average contributions (p value); the L02 cells ranged from 4.07 to 8.50, and the HepG2 cells ranged from 4.08 to 9.43. The specific data are shown in Table 5, and the 16 compounds had a relatively average influence on hepatocyte toxicity. The hepatotoxicity caused by PM may be due to the synergistic result of multiple components. Furthermore, the



average influence value (MIV) of the input variables in the network was used to assess the importance of different variables in the BP-ANN model. Variables negatively correlated with the IC_{50} values were sieved out. For L02 cells, the screened components were X7, X6, X10, X4, X15, X9, X2, X14, and X16. For HepG2 cells, X7, X4, X11, X13, X6, and X14 were selected. In summary, the common components screened were dianthrone components X7 and X14 and anthraquinone glycosides X4 and X6. These components may be of great significance as potential hepatotoxic components in PM.

For the key characteristic components screened out using the above three models, the intersection of these components included X6, X7, and X14. It was thought that they may play a more significant role in liver injury caused by PM and could be used as toxicity markers of hepatotoxicity. We acknowledge that PM has complex chemical components and that its hepatotoxicity may be the result of the synergistic action of various components. The 16 components screened above all contained a degree of hepatotoxicity. Moreover, there were many potentially hepatotoxic compounds that we had not discovered and identified that need to be further explored and verified.

4 Discussion

As an invaluable treasure of Chinese civilization, Chinese herbal medicine has the characteristics of multiple components, multiple targets, and multiple pathways. Many previous studies have explored the material basis of PM-induced hepatotoxicity through different methods. The results showed that it was not one type of compound that was responsible for hepatotoxicity in PM, which reflected the complexity and holistic nature of TCM. The hepatotoxicity may be a synergistic effect caused by multiple components acting on multiple targets leading to the toxicity result. In this study, MS fingerprints were combined with pharmacological toxicity to target potential hepatotoxic compounds in PM. Sixteen compounds were found to be associated with hepatotoxicity, potentially including dianthrones X7, X8, X9, X12, X13, X14, X15, and X16; anthraquinone glycosides X3, X4, and X6; stilbene glycosides X10 and X11; and flavanols X1, X2, and X5.

It was noteworthy that the dianthrones were the first compounds found by our team to have hepatotoxicity (Yang et al., 2021). The cis- and trans-structures of X7 were shown to

Compound	p Valu	e	MIV	
	L02	HepG2	L02	HepG2
X1	4.07	7.57	0.009	0.015
X2	5.01	9.43	-0.029	0.004
X3	7.29	5.69	0.105	0.029
X4	7.03	6.51	-0.046	-0.131
X5	6.60	4.08	0.002	0.062
X6	7.35	6.05	-0.089	-0.023
X7	6.40	7.40	-0.161	-0.247
X8	8.50	6.19	0.086	0.145
X9	4.99	6.21	-0.038	0.020
X10	7.61	6.63	-0.055	0.033
X11	5.77	6.19	0.022	-0.103
X12	8.12	5.91	0.072	0.178
X13	5.47	6.07	0.002	-0.102
X14	4.88	5.32	-0.015	-0.006
X15	5.70	4.95	-0.040	0.004
X16	5.22	5.79	-0.013	0.032

have IC₅₀ values of 10.98 and 15.45 μ M, respectively, in the HepaRG cytotoxicity evaluation. The 96-h LD₅₀ of (*cis/trans*) X7 in zebrafish embryos was 1.79 and 1.70 μ M (Yang J. B. et al., 2018). X7 exhibited hepatotoxicity at a relatively low concentration of 0.5 mg/L in a zebrafish hepatotoxicity model (Li et al., 2020). X12 exhibited weak hepatotoxicity in L02 cells using the CCK-8 assay (Yang et al., 2016). Moreover, the 96-h LD₅₀ of X12 (C4) was 3.39 μ M in zebrafish embryos, and a delayed appearance of liver yolk sacs in zebrafish occurred at 0.25 mg/L, indicating definite hepatotoxicity with IC₅₀ values of 29.7–31.1 μ M against KB tumor cell lines (Yang J. et al., 2018). The hepatotoxicity of other dianthrones still needs further investigation.

Regarding the screened anthraquinone glycoside components, studies have shown that X3 displayed moderate hepatotoxicity with an IC₅₀ value of 71.62 μ M in HepG2 cells (Hanh et al., 2021). The 96-h LD₅₀ of X3 in zebrafish embryos was 1.10 μ M (Yang J. B. et al., 2018). In addition, X3 exhibited zebrafish hepatotoxicity at a low concentration of 0.25 mg/L (Li et al., 2020). However, the structure of X4 is similar to that of X3, with the methoxy group changed to the hydroxyl group on the benzene ring. Moreover, X6 was demonstrated to have strong embryotoxicity and hepatotoxicity in zebrafish in the toxicity test (Yang J. B. et al., 2018; Li et al., 2020). In addition, X6 inhibited the mRNA expression of CYP1A2 and CYP2C and moderately inhibited the activity of UDP-glucuronosyl transferase (UGT1A1), which was suspected to contribute to hepatotoxicity (Jiang et al., 2022).

The hepatotoxic components of the stilbene glycosides screened were 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-(2-O-monogalloylesters)-glucopyranoside (X10) and polygonibene E (X11). X10 is a stilbene glycoside, and X11 is a stilbene glycoside dimer. At present, few pharmacological studies have been conducted on the above two stilbene glycoside components. However, some studies have reported that the stilbene glycoside component 2,3,5,4'tetrahydroxystilbene-2-O- β -D-glucoyranoside could be a risk factor for hepatotoxicity in PM, which indicates that there may be some potential for hepatotoxicity of stilbene glycosides (Meng et al., 2017).

Regarding the flavanol compounds X1, X2, and X5, oxidation and polymerization have been reported to be the main reasons for the reduction of catechins and flavonoids after processing (Xiang et al., 2021). It has been stated that these polyphenols cause different forms of toxicity, including organ toxicity, genotoxicity, mutagenicity, and cytotoxicity (Islam et al., 2021). For instance, studies have shown that catechin (X1) has antitumor effects and can induce tumor cell apoptosis on account of certain cytotoxicity (Miyamoto et al., 2004). In addition, studies have reported that epicatechin has a concentrationdependent inhibitory effect on tumor cell proliferation and promotes cell death through apoptosis (Varela-Castillo et al., 2018). Epicatechin-3-O-gallate (ECG, X5) induced apoptosis a TGF-beta superfamily through protein, NAG-1 (nonsteroidal antiinflammatory drug-activated gene) (Baek et al., 2004). ECG is a strong inducer of NAG-1, and action on HCT-116 cells leads to an increase in the G (1) phase, leading to cleavage of polyribose polymerase, a phenomenon consistent with apoptosis. In addition, ECG has also been shown to be cytotoxic and hepatotoxic in vivo and highly toxic to HSC-2 cancer cells (Babich et al., 2005; Galati et al., 2006).

Other studies have shown that emodin, chrysophanol, and physcion anthraquinones in PM could affect bile acid homeostasis and cause hepatotoxicity (Kang et al., 2022). Some studies also concluded that *cis*-2,3,5,4'-tetrahydroxy-trans-stilbene-2-O- β -D-glucoside (*cis*-TSG) in PM led to hepatotoxicity through mitochondrial injury (Liu et al., 2022). In addition, cis-TSG was shown to be more closely related to immunological idiosyncratic hepatotoxicity (Meng et al., 2017). Other views also suggested that the synergy between stilbenes and emodin derivatives contributed to hepatotoxicity of PM (Zhang et al., 2020).

In summary, the 16 chemical components all had different degrees of hepatotoxicity and may be responsible for the hepatotoxicity of PM through a synergistic effect. Among these compounds, the three more typical compounds—emodin dianthrones, emodin-8-O- β -D-glucopyranoside, and PM 14–17—showed strong hepatotoxicity in different models. They may be the key hepatotoxic components in PM. However, there were still many limitations in our experiments, such as the toxicity evaluation involving only *in vitro* cells. In addition, the screened

hepatotoxic compounds lacked standards, and no further toxicity validation was performed.

5 Conclusion

The complexity and diversity of Chinese medicinal components make the discovery of toxic components in Chinese medicine a challenging task. This study integrated a progressive strategy to explore the hepatotoxic components in PM. First, 112 constituents of PM were characterized using UPLC-Q-TOF-MS. Second, plant metabolomics was used to screen for differential components between raw and processed PM. Third, the pseudotargeted mass spectra of the 16 components of 50 batches of PM were established. Then, the hepatotoxicity of 50 batches of PM was evaluated in two hepatocytes. At last, based on three models, GRA, OPLS, and BP-ANN, a spectrum-effect relationship was established to determine the hepatotoxic components in PM. As a result, 16 components with potential hepatotoxicity were found, among which emodin dianthrones, emodin-8-O-β-D-glucopyranoside, and PM 14-17 were more significantly prominent. These three markers could be used as hepatotoxic markers in PM as well as for indepth pharmacological and toxicological studies.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Author contributions

YS, FW, and SM designed and conceived the experiments; YS, XH, PW, HG, and XW carried out the experiments; YS, JY,

References

Babich, H., Krupka, M. E., Nissim, H. A., and Zuckerbraun, H. L. (2005). Differential *in vitro* cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. *Toxicol. Vitro* 19 (2), 231–242. doi:10. 1016/j.tiv.2004.09.001

Baek, S. J., Kim, J. S., Jackson, F. R., Eling, T. E., McEntee, M. F., Lee, S. H., et al. (2004). Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. *Carcinogenesis* 25 (12), 2425–2432. doi:10.1093/carcin/bgh255

But, P. P., Tomlinson, B., and Lee, K. L. (1996). Hepatitis related to the Chinese medicine Shou-Wu-pian manufactured from Polygonum multiflorum. *Vet. Hum. Toxicol.* 38 (4), 280–282.

Chinese Pharmacopoeia Commission (2020). Pharmacopoeia of people's Republic of China. Beijing: China Medical Science Press.

Galati, G., Lin, A., Sultan, A. M., and O'Brien, P. J. (2006). Cellular and *in vivo* hepatotoxicity caused by green tea phenolic acids and catechins. *Free Radic. Biol. Med.* 40 (4), 570–580. doi:10.1016/j.freeradbiomed.2005. 09.014

XH, and XC did the data analysis; YS, JY, and YL contributed to writing and supervising the manuscript; FW and SM funded the study. All authors reviewed and approved the final manuscript.

Funding

The work was financially supported by the National Natural Science Foundation of China (Grant No. 81973476 and 81773874) and National Major Scientific and Technological Special Project for "Significant New Drugs Development" (2018ZX09735006).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar. 2022.935336/full#supplementary-material

Han, L., Wang, P., Wang, Y., Zhao, Q., Zheng, F., Dou, Z., et al. (2019). Rapid discovery of the potential toxic compounds in Polygonum multiflorum by UHPLC/ Q-Orbitrap-MS-Based metabolomics and correlation analysis. *Front. Pharmacol.* 10, 329. doi:10.3389/fphar.2019.00329

Hanh, T. T. H., Anh, L. N., Trung, N. Q., Quang, T. H., Anh, D. H., Cuong, N. X., et al. (2021). Cytotoxic phenolic glycosides from the seeds of Senna tora. *Phytochem. Lett.* 45, 190–194. doi:10.1016/j.phytol.2021.08.020

Islam, B. U., Suhail, M., Khan, M. K., Zughaibi, T. A., Alserihi, R. F., Zaidi, S. K., et al. (2021). Polyphenols as anticancer agents: Toxicological concern to healthy cells. *Phytother. Res.* 35 (11), 6063–6079. doi:10.1002/ptr.7216

Jiang, Y., Zhang, C., Zheng, X., Zhao, Z., and Li, H. J. (2022). Simultaneously screening multiple UGT1A1 inhibitors from Polygonum multiflorum root using ultrafiltration LC-MS. *Biomed. Chromatogr.* 36 (4), e5300. doi:10.1002/bmc.5300

Jiang, Z., Zhao, C., Gong, X., Sun, X., Li, H., Zhao, Y., et al. (2018). Quantification and efficient discovery of quality control markers for Emilia prenanthoidea DC. by Fingerprint-Efficacy Relationship Modelling. *J. Pharm. Biomed. Anal.* 156, 36–44. doi:10.1016/j.jpba.2018.04.020 Kang, L., Li, D., Jiang, X., Zhang, Y., Pan, M., Hu, Y., et al. (2022). Hepatotoxicity of the major anthraquinones derived from polygoni multiflori radix based on bile acid homeostasis. *Front. Pharmacol.* 13, 878817. doi:10.3389/fphar.2022.878817

Lei, X., Chen, J., Ren, J., Li, Y., Zhai, J., Mu, W., et al. (2015). Liver damage associated with Polygonum multiflorum Thunb.: A systematic review of case reports and case series. *Evid. Based. Complement. Altern. Med.* 2015, 459749. doi:10.1155/2015/459749

Li, H. Y., Yang, J. B., Li, W. F., Qiu, C. X., Hu, G., Wang, S. T., et al. (2020). *In vivo* hepatotoxicity screening of different extracts, components, and constituents of Polygoni Multiflori Thunb. in zebrafish (*Danio rerio*) larvae. *Biomed. Pharmacother.* 131, 110524. doi:10.1016/j.biopha.2020.110524

Liang, J., Chen, Y., Ren, G., Dong, W., Shi, M., Xiong, L., et al. (2017). Screening hepatotoxic components in euodia rutaecarpa by UHPLC-QTOF/MS based on the spectrum-toxicity relationship. *Molecules* 22 (8), E1264. doi:10.3390/molecules22081264

Liao, M., Yan, P., Liu, X., Du, Z., Jia, S., Aybek, R., et al. (2020). Spectrum-effect relationship for anti-tumor activity of shikonins and shikonofurans in medicinal Zicao by UHPLC-MS/MS and chemometric approaches. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 1136, 121924. doi:10.1016/j.jchromb.2019.121924

Lin, L., Ni, B., Lin, H., Zhang, M., Li, X., Yin, X., et al. (2015). Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review. *J. Ethnopharmacol.* 159, 158–183. doi:10.1016/j.jep.2014.11.009

Liu, J., Li, T., Li, R., Wang, J., Li, P., Niu, M., et al. (2022). Hepatic organoid-based high-content imaging boosts evaluation of stereoisomerism-dependent hepatotoxicity of stilbenes in herbal medicines. *Front. Pharmacol.* 13, 862830. doi:10.3389/fphar.2022.862830

Liu, S., Liang, Y. Z., and Liu, H. T. (2016). Chemometrics applied to quality control and metabolomics for traditional Chinese medicines. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 1015-1016, 82–91. doi:10.1016/j.jchromb.2016.02.011

Liu, Y., Wang, Q., Yang, J., Guo, X., Liu, W., Ma, S., et al. (2018). Polygonum multiflorum Thunb.: A review on chemical analysis, processing mechanism, quality evaluation, and hepatotoxicity. *Front. Pharmacol.* 9, 364. doi:10.3389/fphar.2018.00364

Luo, P., Dai, W., Yin, P., Zeng, Z., Kong, H., Zhou, L., et al. (2015). Multiple reaction monitoring-ion pair finder: A systematic approach to transform nontargeted mode to pseudotargeted mode for metabolomics study based on liquid chromatography-mass spectrometry. *Anal. Chem.* 87 (10), 5050–5055. doi:10.1021/acs.analchem.5b00615

Ma, Y., Li, J., Tong, F., Xin, X.-L., and Aisa, H. A. (2020). Optimization of microwave-assisted extraction using response surface methodology and the potential anti-diabetic efficacy of Nigella glandulifera Freyn determined using the spectrum-effect relationship. *Industrial Crops Prod.* 153, 112592. doi:10. 1016/j.indcrop.2020.112592

Meng, Y. K., Li, C. Y., Li, R. Y., He, L. Z., Cui, H. R., Yin, P., et al. (2017). Cisstilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR- γ . *Acta Pharmacol. Sin.* 38 (10), 1340–1352. doi:10.1038/aps.2017.32

Miyamoto, Y., Haylor, J. L., and El Nahas, A. M. (2004). Cellular toxicity of catechin analogues containing gallate in opossum kidney proximal tubular (OK) cells. J. Toxicol. Sci. 29 (1), 47–52. doi:10.2131/jts.29.47

Park, G. J., Mann, S. P., and Ngu, M. C. (2001). Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. *J. Gastroenterol. Hepatol.* 16 (1), 115–117. doi:10.1046/j.1440-1746.2001.02309.x

Qiao, X., Qu, C., Luo, Q., Wang, Y., Yang, J., Yang, H., et al. (2021). UHPLC-qMS spectrum-effect relationships for Rhizoma Paridis extracts. *J. Pharm. Biomed. Anal.* 194, 113770. doi:10.1016/j.jpba.2020.113770

Rao, S. W., Duan, Y. Y., Pang, H. Q., Xu, S. H., Hu, S. Q., Cheng, K. G., et al. (2022). Spectrum-effect relationship analysis of bioactive compounds in zanthoxylum nitidum (roxb.) DC. By ultra-high performance liquid chromatography mass spectrometry coupled with comprehensive filtering approaches. *Front. Pharmacol.* 13, 794277. doi:10.3389/fphar.2022.794277

Shang, Z., Xu, L., Zhang, Y., Ye, M., and Qiao, X. (2021). An integrated approach to reveal the chemical changes of Ligustri Lucidi Fructus during wine steaming processing. *J. Pharm. Biomed. Anal.* 193, 113667. doi:10.1016/j.jpba. 2020.113667

Shi, W., Zhang, C., Zhao, D., Wang, L., Li, P., Li, H., et al. (2018). Discovery of hepatotoxic equivalent combinatorial markers from Dioscorea bulbifera tuber by fingerprint-toxicity relationship modeling. *Sci. Rep.* 8 (1), 462. doi:10.1038/s41598-017-18929-z

Teka, T., Wang, L., Gao, J., Mou, J., Pan, G., Yu, H., et al. (2021). Polygonum multiflorum: Recent updates on newly isolated compounds, potential hepatotoxic compounds and their mechanisms. *J. Ethnopharmacol.* 271, 113864. doi:10.1016/j. jep.2021.113864

Varela-Castillo, O., Cordero, P., Gutiérrez-Iglesias, G., Palma, I., Rubio-Gayosso, I., Meaney, E., et al. (2018). Characterization of the cytotoxic effects of the combination of cisplatin and flavanol (-)-epicatechin on human lung cancer cell line A549. An isobolographic approach. *Exp. Oncol.* 40 (1), 19–23. doi:10.31768/2312-8852.2018.40(1):19-23

Wang, F., Wang, B., Wang, L., Xiong, Z. Y., Gao, W., Li, P., et al. (2017). Discovery of discriminatory quality control markers for Chinese herbal medicines and related processed products by combination of chromatographic analysis and chemometrics methods: Radix Scutellariae as a case study. *J. Pharm. Biomed. Anal.* 138, 70–79. doi:10.1016/j.jpba.2017.02.004

Wang, J., Luo, D., Liang, M., Zhang, T., Yin, X., Zhang, Y., et al. (2018). Spectrum-effect relationships between high-performance liquid chromatography (HPLC) fingerprints and the antioxidant and antiinflammatory activities of collagen peptides. *Molecules* 23 (12), E3257. doi:10.3390/molecules23123257

Wang, Q., Yan, M., Ma, S., and Wen, H. (2021). Predicting toxic monomer components in Polygonum multiflorum based on quantitative structure-activity relationship. *Chin. J. Pharmacovigil.* 18 (4), 352–360. doi:10.19803/j.1672-8629. 2021.04.12

Xiang, X., Su, C., Shi, Q., Wu, J., Zeng, Z., Zhang, L., et al. (2021). Potential hypoglycemic metabolites in dark tea fermented by Eurotium cristatum based on UPLC-QTOF-MS/MS combining global metabolomic and spectrum-effect relationship analyses. *Food Funct.* 12 (16), 7546–7556. doi:10. 1039/d1fo00836f

Xu, J. F., Xu, J., Li, S. Z., Jia, T. W., Huang, X. B., Zhang, H. M., et al. (2013). Transmission risks of schistosomiasis japonica: Extraction from back-propagation artificial neural network and logistic regression model. *PLoS Negl. Trop. Dis.* 7 (3), e2123. doi:10.1371/journal.pntd.0002123

Yang, J. B., Li, L., Dai, Z., Wu, Y., Geng, X. C., Li, B., et al. (2016). Polygonumnolides C1-C4; minor dianthrone glycosides from the roots of Polygonum multiflorum Thunb. *J. Asian Nat. Prod. Res.* 18 (9), 813–822. doi:10.1080/10286020.2016.1171758

Yang, J. B., Li, W. F., Liu, Y., Wang, Q., Cheng, X. L., Wei, F., et al. (2018b). Acute toxicity screening of different extractions, components and constituents of Polygonum multiflorum Thunb. on zebrafish (*Danio rerio*) embryos *in vivo*. *Biomed. Pharmacother.* 99, 205–213. doi:10.1016/j.biopha.2018.01.033

Yang, J. B., Song, Y. F., Liu, Y., Gao, H. Y., Wang, Q., Wang, Y., et al. (2021). UHPLC-QQQ-MS/MS assay for the quantification of dianthrones as potential toxic markers of Polygonum multiflorum Thunb: Applications for the standardization of traditional Chinese medicines (TCMs) with endogenous toxicity. *Chin. Med.* 16 (1), 51. doi:10.1186/s13020-021-00463-w

Yang, J., Yan, Z., Ren, J., Dai, Z., Ma, S., Wang, A., et al. (2018a). Polygonumnolides A1-B3, minor dianthrone derivatives from the roots of Polygonum multiflorum Thunb. *Arch. Pharm. Res.* 41 (6), 617–624. doi:10. 1007/s12272-016-0816-7

Zhang, C., Zheng, X., Ni, H., Li, P., and Li, H. J. (2018). Discovery of quality control markers from traditional Chinese medicines by fingerprint-efficacy modeling: Current status and future perspectives. *J. Pharm. Biomed. Anal.* 159, 296–304. doi:10.1016/j.jpba.2018.07.006

Zhang, L., Liu, X., Tu, C., Li, C., Song, D., Zhu, J., et al. (2020). Components synergy between stilbenes and emodin derivatives contributes to hepatotoxicity induced by Polygonum multiflorum. *Xenobiotica*. 50 (5), 515–525. doi:10.1080/00498254.2019.1658138

Zheng, F., Zhao, X., Zeng, Z., Wang, L., Lv, W., Wang, Q., et al. (2020). Development of a plasma pseudotargeted metabolomics method based on ultrahigh-performance liquid chromatography-mass spectrometry. *Nat. Protoc.* 15 (8), 2519–2537. doi:10.1038/s41596-020-0341-5